TELA BioTELA -4.54%54 FCF Margin % is -59.23% as of Mar. 2026. GuruFocus rates TELA with a GF Score™ of 54/100 and a GF Value™ of $1.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, TELA Bio ranks worse than 76.2% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TELA Bio's Free Cash Flow for the
three
months ended in Mar. 2026 was $-11.29 Mil. TELA Bio's Revenue for the
three
months ended in Mar. 2026 was $19.06 Mil. Therefore, TELA Bio's FCF Margin % for the quarter that ended in Mar. 2026 was -59.23%.
The historical rank and industry rank for TELA Bio's FCF Margin % or its related term are showing as below:
TELA'
s FCF Margin % Range Over the Past 10 Years
Min: -388.27 Med: -105.42 Max: -35.71
Current: -37.37
During the past 9 years, the highest FCF Margin % of TELA Bio was -35.71%. The lowest was -388.27%. And the median was -105.42%.
TELA's FCF Margin % is ranked worse than 76.2% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs TELA: -37.37
TELA Bio FCF Margin % Related Terms
TELA Bio FCF Margin % Historical Data
* Premium members only.
The historical data trend for TELA Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TELA Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TELA Bio FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where TELA Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA Bio (TELA) has a FCF Margin % of -59.23% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TELA Bio and its competitors. According to the industry distribution chart, TELA Bio ranks #621 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 76.2%.
Is TELA Bio's FCF Margin % too high?
TELA Bio's current FCF Margin % is -59.23%. Based on the distribution chart, TELA Bio ranks #621 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TELA Bio has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's FCF Margin % compare to NSPR and PAVM?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #621 out of 815 companies for FCF Margin %. This places TELA Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TELA Bio and its competitors. TELA Bio's current FCF Margin % is -59.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.67, compared to a current price of $0.75 — trading 55.1% below its estimated fair value. The current FCF Margin % is -59.23%. TELA Bio's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TELA Bio (TELA), the current FCF Margin % is -59.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TELA Bio (TELA) Overvalued in 2026?
Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued.
The current stock price of $0.75 is trading 55.1% below its estimated GF Value™ of $1.67.
GuruFocus considers TELA Bio to be Possible Value Trap.
Key valuation signals for TELA:
FCF Margin %: -59.23%
GF Value™: $1.67 vs. price of $0.75 (55.1% below fair value)
No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
54GF Score
Get the complete analysis for TELA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELA has been successfully added to your 
